S Mosconi
Overview
Explore the profile of S Mosconi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, et al.
ESMO Open
. 2021 Aug;
6(5):100238.
PMID: 34392104
Background: Germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-related pancreatic ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents. This study aimed at exploring safety profile, dose intensity, and activity of different...
2.
Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, et al.
Ann Oncol
. 2016 Nov;
28(3):555-561.
PMID: 27864220
Background: Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials,...
3.
Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, et al.
Cancer Chemother Pharmacol
. 2015 Dec;
77(1):109-14.
PMID: 26659366
Purpose: Advanced biliary tract adenocarcinoma (BTA) is a rare tumor with a poor prognosis. Since no standard salvage chemotherapy regimen exists, we explored the activity of capecitabine alone or combined...
4.
Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, et al.
Ann Oncol
. 2014 Apr;
25(7):1373-1378.
PMID: 24728035
Background: Some trial have demonstrated a benefit of adjuvant fluoropirimidine with or without platinum compounds compared with surgery alone. ITACA-S study was designed to evaluate whether a sequential treatment of...
5.
Labianca R, Nordlinger B, Beretta G, Mosconi S, Mandala M, Cervantes A, et al.
Ann Oncol
. 2013 Oct;
24 Suppl 6:vi64-72.
PMID: 24078664
No abstract available.
6.
Labianca R, Merelli B, Mosconi S
Ann Oncol
. 2012 Sep;
23 Suppl 10:x139-40.
PMID: 22987950
No abstract available.
7.
Labianca R, Milesi L, Mosconi S, Pessi M, Beretta G, Quadri A
Surg Oncol
. 2008 Feb;
16 Suppl 1:S93-6.
PMID: 18257148
Surgical resection of the primary and regional lymph nodes is still, at this time, the standard treatment of colon cancer. However, the risk of recurrence is still high in many...
8.
Mandala M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S, et al.
Ann Oncol
. 2007 Jul;
18(10):1660-5.
PMID: 17660490
Background: The aim was to investigate the outcomes associated with venous thromboembolism (VTE) among irresectable pancreatic cancer patients. Methods: This is a follow-up study of consecutive irresectable cancer patients, treated...
9.
Labianca R, Mosconi S, Garassino M
Ann Oncol
. 2006 Jun;
17 Suppl 7:vii51-4.
PMID: 16760294
Adjuvant therapy in colorectal cancer has always been a controversy during years. Despite the fact that benefit of adjuvant therapy in stage III is clear, a more controversial question concerns...
10.
Labianca R, Beretta G, Mosconi S, Milesi L, Pessi M
Ann Oncol
. 2005 Jun;
16 Suppl 2:ii127-32.
PMID: 15958442
No abstract available.